Takafumi Suda Selected Research

Drug Therapy (Chemotherapy)

3/2022	Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.
1/2022	Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study.
1/2022	Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report.
12/2021	Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy.
7/2021	Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials.
1/2021	Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.
4/2020	Pneumocystis jirovecii Pneumonia in a Patient with Breast Cancer Receiving Neoadjuvant Dose-dense Chemotherapy.
1/2020	Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy.
1/2019	Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
9/2018	Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takafumi Suda Research Topics

Disease

44	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 07/2003
40	Neoplasms (Cancer) 10/2022 - 12/2004
38	Idiopathic Pulmonary Fibrosis 01/2022 - 07/2005
35	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 09/2003
25	Asthma (Bronchial Asthma) 05/2022 - 09/2002
19	Lung Neoplasms (Lung Cancer) 01/2022 - 09/2003
17	Inflammation (Inflammations) 01/2022 - 09/2002
17	Infections 02/2021 - 01/2005
16	Chronic Obstructive Pulmonary Disease (COPD) 05/2022 - 12/2008
16	Disease Progression 01/2022 - 03/2010
16	Pneumonia (Pneumonitis) 03/2021 - 04/2004
12	Dermatomyositis (Dermatopolymyositis) 01/2022 - 05/2009
12	Idiopathic Interstitial Pneumonias 01/2022 - 01/2006
12	Respiratory Insufficiency (Respiratory Failure) 01/2020 - 09/2002
11	Sarcoidosis (Schaumann Disease) 08/2020 - 01/2005
10	Adenocarcinoma of Lung 01/2022 - 01/2017
10	Vascular Diseases (Vascular Disease) 03/2021 - 07/2006
10	Lung Diseases (Lung Disease) 01/2021 - 04/2008
9	Nausea 03/2022 - 06/2014
9	Cough 04/2016 - 12/2006
8	Fibrosis (Cirrhosis) 01/2021 - 07/2005
8	Rheumatoid Arthritis 08/2020 - 09/2008
8	Dyspnea (Shortness of Breath) 08/2019 - 12/2006
7	Vomiting 03/2022 - 06/2014
7	Tuberculosis (Tuberculoses) 03/2012 - 04/2006
6	Hemorrhage 01/2020 - 07/2005
6	Hypoxia (Hypoxemia) 01/2019 - 01/2008
6	Neoplasm Metastasis (Metastasis) 12/2018 - 11/2013
6	Fever (Fevers) 05/2018 - 12/2006
5	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 08/2015
5	Granuloma 04/2016 - 06/2002
4	Pulmonary Eosinophilia (Eosinophilic Pneumonia) 01/2022 - 06/2015
4	Connective Tissue Diseases (Connective Tissue Disease) 01/2022 - 10/2010
4	Cryptogenic Organizing Pneumonia 01/2022 - 10/2004
4	Myositis (Idiopathic Inflammatory Myopathies) 01/2022 - 01/2014
4	Organizing Pneumonia 11/2020 - 01/2007
4	Breast Neoplasms (Breast Cancer) 04/2020 - 10/2004
4	Bronchiectasis 01/2018 - 01/2013
4	Extrinsic Allergic Alveolitis (Hypersensitivity Pneumonitis) 04/2016 - 12/2006
4	Pleural Effusion (Pleural Effusions) 01/2016 - 06/2002
3	Carcinogenesis 10/2022 - 09/2003
3	Death (Near-Death Experience) 04/2022 - 11/2020
3	Adenocarcinoma 01/2022 - 01/2017
3	Amyopathic dermatomyositis 01/2022 - 05/2009
3	Eosinophilia 01/2022 - 09/2013

Drug/Important Bio-Agent (IBA)

30	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2021 - 09/2005
14	Proteins (Proteins, Gene)FDA Link 07/2022 - 02/2008
14	Pharmaceutical PreparationsIBA 01/2022 - 11/2004
14	Biomarkers (Surrogate Marker)IBA 11/2021 - 11/2011
13	Carboplatin (JM8)FDA LinkGeneric 03/2022 - 09/2012
13	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2019 - 09/2006
12	CollagenIBA 03/2021 - 07/2006
11	AutoantibodiesIBA 01/2022 - 01/2006
11	SteroidsIBA 04/2019 - 09/2002
10	Prednisolone (Predate)FDA LinkGeneric 01/2021 - 07/2005
9	AntibodiesIBA 01/2022 - 01/2008
8	AntiemeticsIBA 03/2022 - 06/2014
8	ErbB Receptors (EGF Receptor)IBA 01/2021 - 08/2011
8	Messenger RNA (mRNA)IBA 01/2020 - 09/2002
7	Dexamethasone (Maxidex)FDA LinkGeneric 03/2022 - 06/2014
7	Immune Checkpoint InhibitorsIBA 10/2021 - 05/2016
7	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 08/2011
7	EnzymesIBA 01/2021 - 09/2008
7	CytokinesIBA 03/2019 - 09/2002
7	VaccinesIBA 11/2015 - 04/2008
6	NivolumabIBA 02/2022 - 01/2019
6	LigandsIBA 02/2022 - 07/2005
6	pirfenidoneIBA 07/2021 - 01/2014
6	Methotrexate (Mexate)FDA LinkGeneric 07/2021 - 05/2012
6	Anti-Bacterial Agents (Antibiotics)IBA 02/2021 - 04/2008
6	ImmunosorbentsIBA 01/2021 - 09/2008
6	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2021 - 05/2008
6	AntigensIBA 01/2020 - 06/2002
6	Budesonide (Pulmicort)FDA LinkGeneric 01/2019 - 09/2005
5	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 01/2022 - 01/2015
5	LipidsIBA 01/2022 - 01/2005
5	Bevacizumab (Avastin)FDA Link 01/2021 - 01/2016
5	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2021 - 07/2003
5	Peroxidase (Myeloperoxidase)IBA 01/2021 - 05/2008
5	Formoterol Fumarate (Oxis)FDA Link 01/2019 - 06/2012
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 07/2005
5	Therapeutic UsesIBA 01/2015 - 05/2008
4	Oxygen (Dioxygen)IBA 04/2022 - 03/2017
4	Tyrosine Kinase InhibitorsIBA 01/2022 - 07/2015
4	Immunoglobulin G (IgG)IBA 01/2022 - 07/2005
4	Mannose ReceptorIBA 02/2020 - 01/2018
4	Rifampin (Rifampicin)FDA LinkGeneric 01/2020 - 04/2006
4	Clarithromycin (Biaxin)FDA LinkGeneric 01/2020 - 09/2005
4	Immunoglobulin E (IgE)IBA 02/2019 - 07/2005
4	Phenobarbital (Luminal)FDA Link 01/2019 - 06/2013
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 03/2009
4	Tiotropium Bromide (Spiriva)FDA Link 02/2015 - 12/2008
4	AcidsIBA 04/2012 - 01/2005
3	Bronchodilator Agents (Bronchodilators)IBA 05/2022 - 01/2015
3	5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA 03/2022 - 07/2016
3	Olanzapine (Zyprexa)FDA Link 03/2022 - 01/2019

Therapy/Procedure

71	Therapeutics 07/2022 - 06/2002
25	Drug Therapy (Chemotherapy) 03/2022 - 04/2008
4	Artificial Respiration (Mechanical Ventilation) 04/2022 - 02/2005
3	Aftercare (After-Treatment) 01/2022 - 09/2005